Payton Nyquvest

Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE:MBA). The proposed transaction comes as the Vancouver-based company reorganizes its operations with a near-term strategic plan toward...

In this episode of The Dales Report, we’re sitting down with Numinus Wellness CEO Payton Nyquvest for a psychedelic exclusive. Our topic of conversation with Payton today steers into the recent FDA warning and the dynamic world of off-label markets for new compounds. First up: The FDA made...

On this new Psychedelic Series Podcast, TDR Founder Shadd Dales spoke with Payton Nyquvest, CEO of Numinus Wellness Inc. (OTC: NUMIF). The podcast focused on additional feedback regarding the company’s recent second quarter 2023 financial results, an updated picture of the...

Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTCMKTS: IWINF)’ CEO Klee Irwin, Field Trip H&W (OTCMKTS: FTHWF)’s co-founder and director Mujeeb...

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, reported its financial results late Monday for the three and twelve months ended August 31, 2022. "Fiscal 2022 was a...

The Neurology Centre of Toronto (NCT), located in a midtown neighborhood and owned by Numinus Wellness Inc. (OTCQX: NUMIF), is offering ketamine-assisted therapy for patients with neurologic conditions diagnoses. Numinus is focused on delivering evidence-based, innovative and safe...

Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX: NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.  The results do not reflect contributions from the acquisition of Novamind, completed after...

Numinus Wellness Inc. (OTCQX: NUMIF) sent a patent application to the World Intellectual Property Organization (WIPO) through its subsidiary, Numinus Bioscience Inc., for a prompt production process for Psilocybe and other fungi species containing psilocybin and variant compounds. WIPO is the...

Numinus Wellness Inc. (OTCQX: NUMIF), a company focused on the development and delivery of innovative mental health care through evidence-based psychedelic-assisted therapies, announced that its shareholders approved the issuance of common shares in connection with the proposed acquisition of...

Numinus Wellness Inc. (TSX:NUMI)(OTCQX: NUMIF) and Novamind Inc. (CSE:NM)(OTCQB: NVMDF)(FSE:HN2) have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of a court-...

Numinus Wellness Inc (TSX: NUMI) (OTC: NUMIF) reported its fiscal first-quarter results Thursday for the three months ended Nov. 30, 2021. Based in Vancouver, the company said that it ended the quarter strong with a cash position of CA$53.9 million ($43.15 million) "We have made...

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV: NUMI) (OTCQX: NUMIF) announced its fiscal fourth quarter and full-year results Thursday for the periods ended August 31, 2021, with quarterly revenue of CA$500,000 ($394,153) up by 81% from...

In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.  The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming...

Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to...